Clinical Trial

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (6.0M jCell) compared to sham-treated controls.
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-07-31
notable Enrollment reduced: 60 -> 31 participants 2026-07-31
notable Primary completion pushed: 2026-09 -> 2026-12 2026-07-31
minor Completion pushed: 2026-09 -> 2026-12 2026-07-31
Trial Details
NCT Number NCT06912633
Lead Sponsor jCyte, Inc
Conditions Retinitis Pigmentosa
Enrollment 31 participants
Start Date 2025-06-20
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-30